KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 90 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 1.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $2,255,000 | +67.2% | 218,516 | +70.4% | 0.02% | +57.1% |
| Q1 2021 | $1,349,000 | -35.6% | 128,243 | -5.2% | 0.01% | -41.7% |
| Q4 2020 | $2,095,000 | +3.9% | 135,335 | -2.1% | 0.02% | -11.1% |
| Q3 2020 | $2,017,000 | -34.2% | 138,176 | -14.6% | 0.03% | -37.2% |
| Q2 2020 | $3,065,000 | +15.5% | 161,822 | +17.1% | 0.04% | -2.3% |
| Q1 2020 | $2,654,000 | -37.7% | 138,144 | -37.8% | 0.04% | -18.5% |
| Q4 2019 | $4,260,000 | +97.9% | 222,219 | -0.7% | 0.05% | +80.0% |
| Q3 2019 | $2,153,000 | +59.7% | 223,756 | -0.6% | 0.03% | +57.9% |
| Q2 2019 | $1,348,000 | +2.7% | 225,001 | +0.1% | 0.02% | 0.0% |
| Q1 2019 | $1,313,000 | +3.5% | 224,854 | +66.2% | 0.02% | -9.5% |
| Q4 2018 | $1,268,000 | -45.0% | 135,315 | 0.0% | 0.02% | -36.4% |
| Q3 2018 | $2,304,000 | -12.8% | 135,315 | -13.0% | 0.03% | -15.4% |
| Q2 2018 | $2,642,000 | +26.6% | 155,525 | 0.0% | 0.04% | +21.9% |
| Q1 2018 | $2,087,000 | +39.8% | 155,525 | 0.0% | 0.03% | +39.1% |
| Q4 2017 | $1,493,000 | -12.0% | 155,525 | +0.7% | 0.02% | -17.9% |
| Q3 2017 | $1,696,000 | +21.3% | 154,449 | 0.0% | 0.03% | +16.7% |
| Q2 2017 | $1,398,000 | -31.9% | 154,449 | -3.4% | 0.02% | -33.3% |
| Q1 2017 | $2,052,000 | +150.9% | 159,807 | +83.6% | 0.04% | +140.0% |
| Q4 2016 | $818,000 | -3.9% | 87,030 | -0.5% | 0.02% | -11.8% |
| Q3 2016 | $851,000 | +45.0% | 87,466 | 0.0% | 0.02% | +41.7% |
| Q2 2016 | $587,000 | -24.7% | 87,466 | 0.0% | 0.01% | -29.4% |
| Q1 2016 | $780,000 | -33.2% | 87,466 | -0.7% | 0.02% | -34.6% |
| Q4 2015 | $1,167,000 | +101.9% | 88,066 | +60.3% | 0.03% | +85.7% |
| Q3 2015 | $578,000 | -46.2% | 54,937 | +39.1% | 0.01% | -41.7% |
| Q2 2015 | $1,074,000 | -11.2% | 39,487 | 0.0% | 0.02% | -7.7% |
| Q1 2015 | $1,209,000 | -20.5% | 39,487 | -2.8% | 0.03% | -23.5% |
| Q4 2014 | $1,521,000 | +8.9% | 40,624 | +1.6% | 0.03% | +3.0% |
| Q3 2014 | $1,397,000 | -24.9% | 39,980 | 0.0% | 0.03% | -25.0% |
| Q2 2014 | $1,861,000 | +42.1% | 39,980 | -5.7% | 0.04% | +37.5% |
| Q1 2014 | $1,310,000 | – | 42,400 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |